Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

CNTX

Context Therapeutics Inc

Dec 11 • 04:00PM ET

1.50

Dollar change -0.06
Percentage change -3.85	%

Healthcare • Biotechnology • USA • NASD

Peers: ONCT ZNTL KYMR CULP NBTX RNAZ BCYC XCUR CARA CGTX

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.91	Insider Own	21.04%	Shs Outstand	75.00M	Perf Week	-0.66%
Market Cap	112.50M	Forward P/E	-	EPS next Y	-0.33	Insider Trans	0.00%	Shs Float	59.22M	Perf Month	-26.47%
Income	-30.15M	PEG	-	EPS next Q	-0.06	Inst Own	55.92%	Short Float	1.36%	Perf Quarter	-30.23%
Sales	0.00M	P/S	-	EPS this Y	64.83%	Inst Trans	0.04%	Short Ratio	2.78	Perf Half Y	-25.00%
Book/sh	1.12	P/B	1.34	EPS next Y	37.44%	ROA	-55.16%	Short Interest	0.80M	Perf Year	72.41%
Cash/sh	1.13	P/C	1.33	EPS next 5Y	-	ROE	-58.98%	52W Range	0.79 - 2.75	Perf YTD	32.74%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-26.70%	ROI	-35.90%	52W High	-45.45%	Beta	2.00
Dividend TTM	-	Quick Ratio	36.91	Sales past 5Y	0.00%	Gross Margin	-	52W Low	89.85%	ATR (14)	0.13
Dividend Ex-Date	-	Current Ratio	36.91	EPS Y/Y TTM	29.85%	Oper. Margin	-	RSI (14)	35.97	Volatility	5.38% 8.42%
Employees	5	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	7.12
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	41.06%	Payout	-	Rel Volume	0.80	Prev Close	1.56
Sales Surprise	-	EPS Surprise	-144.44%	Sales Q/Q	-	Earnings	Nov 06 AMC	Avg Volume	288.71K	Price	1.50
SMA20	-5.21%	SMA50	-19.88%	SMA200	-19.31%	Trades		Volume	230,239	Change	-3.85%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-25-24	Initiated	D. Boral Capital	Buy	$9
May-16-24	Initiated	Piper Sandler	Overweight	$4.50

Nov-06-24 04:06PM	Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results (GlobeNewswire) -5.86%
Oct-23-24 07:30AM	Context Therapeutics to Participate in Upcoming Investor Conferences in November (GlobeNewswire) +11.50%
Oct-16-24 07:30AM	Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting (GlobeNewswire) +5.13%
Sep-23-24 07:30AM	BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody (GlobeNewswire) -7.96%
Sep-12-24 09:40AM	Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year? (Zacks)
07:30AM	Loading…
Sep-04-24 07:30AM	Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors (GlobeNewswire)
Aug-27-24 09:40AM	Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year? (Zacks)
Aug-07-24 04:17PM	Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results (GlobeNewswire)
Aug-01-24 07:30AM	Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations (GlobeNewswire)
Jul-10-24 07:30AM	Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95 (GlobeNewswire)
May-30-24 06:11AM	Hypergrowth Hits: 3 Stocks Clocking Triple-Digit Gains with No End in Sight (InvestorPlace)
May-22-24 08:50PM	The 100%+ Club: Piper Sandler's 3 Top Picks for Triple-Digit Gains (InvestorPlace)
May-20-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Context Therapeutics Inc. (CNTX) is a Great Choice (Zacks)
May-14-24 12:00PM	Context Therapeutics Inc. (CNTX) Upgraded to Buy: Here's Why (Zacks)
May-08-24 11:56PM	CNTX Stock Earnings: Context Therapeutics Beats EPS for Q1 2024 (InvestorPlace) +5.23%
04:06PM	Loading…
04:06PM	Context Therapeutics Reports First Quarter 2024 Operating and Financial Results (GlobeNewswire)
May-02-24 07:31AM	Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76 (GlobeNewswire) +28.68%
07:30AM	Context Therapeutics Announces $100 Million Private Placement (GlobeNewswire)
Apr-01-24 07:30AM	Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers (GlobeNewswire)
Mar-21-24 01:53PM	CNTX Stock Earnings: Context Therapeutics Misses EPS for Q4 2023 (InvestorPlace) -6.96%
07:43AM	Context Therapeutics Reports Full Year 2023 Operating and Financial Results (GlobeNewswire)
Nov-09-23 04:15PM	Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results (GlobeNewswire)
Oct-31-23 09:00AM	Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76 (GlobeNewswire)
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE) +13.64%
Sep-27-23 09:00AM	Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer s (SITC) 38th Annual Meeting (GlobeNewswire) +16.22%
Aug-10-23 02:19PM	Context Therapeutics CEO Marty Lehr notes progress towards the clinic with CTIM-76 in 2Q update (News Direct) +10.64%
Aug-09-23 04:10PM	Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results (GlobeNewswire) -9.62%
Aug-01-23 07:30AM	Context Therapeutics to Participate in Two August 2023 Investor Conferences (GlobeNewswire) +7.27%
Jun-13-23 01:34PM	Context Therapeutics shares #ASCO23 data on CLDN-6 targeted treatments and CTIM-76 update (News Direct)
Jun-03-23 08:27AM	Will Context Therapeutics (NASDAQ:CNTX) Spend Its Cash Wisely? (Simply Wall St.)
04:39PM	Loading…
May-10-23 04:39PM	Context Therapeutics Reports First Quarter 2023 Operating and Financial Results (GlobeNewswire) -6.37%
Apr-24-23 12:01PM	Context Therapeutics CTIM-76 bispecific antibody preclinical data presented at AACR Annual Meeting (News Direct)
Apr-18-23 10:15AM	Significant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ:CNTX) Plans To Make A Difference (ACCESSWIRE)
Apr-04-23 12:00PM	Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on April 5, 2023 (GlobeNewswire)
Apr-03-23 07:30AM	Context Therapeutics to Participate in Two April 2023 Investor Conferences (GlobeNewswire) +5.85%
Mar-22-23 05:08PM	Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates (GlobeNewswire) -7.59%
Mar-15-23 07:30AM	Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 (GlobeNewswire)
Feb-13-23 08:52AM	UPDATE -- Diamond Equity Research Initiates Coverage on Context Therapeutics Inc. (NASDAQ: CNTX) (GlobeNewswire)
Feb-10-23 01:36PM	Lab Notes: Center for Breakthrough Medicines expands offerings; Researchers identify key 'gene signature' (American City Business Journals)
Feb-07-23 12:21PM	Context Therapeutics announces positive responses in Phase 2 OATH clinical trial (News Direct)
Feb-06-23 07:30AM	Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer (GlobeNewswire) +5.27%
Jan-31-23 07:30AM	Context Therapeutics Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer (GlobeNewswire) +55.20%
Jan-09-23 07:30AM	Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers (GlobeNewswire) +8.32%
Jan-04-23 07:30AM	Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones (GlobeNewswire) +9.79%
Dec-08-22 07:30AM	Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer (GlobeNewswire) -28.42%
Nov-29-22 07:30AM	Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors (GlobeNewswire)
Nov-27-22 07:36AM	Is Context Therapeutics (NASDAQ:CNTX) In A Good Position To Invest In Growth? (Simply Wall St.)
Nov-21-22 09:11AM	Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium (GlobeNewswire)
Nov-09-22 04:14PM	Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results (GlobeNewswire)
Oct-20-22 07:30AM	Context Therapeutics to Participate in the ThinkEquity Conference (Newsfile)
Sep-27-22 11:41AM	Context Therapeutics halting 'noncritical R&D' spending to extend cash runway (American City Business Journals)
07:30AM	Context Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024 (GlobeNewswire)
Sep-06-22 12:50PM	A number of insiders bought Context Therapeutics Inc. (NASDAQ:CNTX) stock last year, which is great news for shareholders (Simply Wall St.)
07:30AM	Context Therapeutics® to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-11-22 04:01PM	Context Therapeutics® Reports Second Quarter 2022 Operating and Financial Results (GlobeNewswire) +9.73%
Aug-02-22 10:49AM	Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination (PR Newswire) +5.82%
Jul-05-22 09:22PM	'I wanted to build it here': Life sciences startup leaders talk about challenges of growing in Philadelphia (American City Business Journals)
May-15-22 10:12AM	Is Context Therapeutics (NASDAQ:CNTX) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
May-11-22 04:01PM	Context Therapeutics® Reports First Quarter 2022 Operating and Financial Results (GlobeNewswire) -5.15% +6.98%
May-05-22 07:30AM	Context Therapeutics® Announces Poster Presentation at the Upcoming 2022 ASCO Annual Meeting (GlobeNewswire)
Apr-11-22 07:30AM	Context Therapeutics® Announces Encouraging Preclinical Data from Two Programs to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022 (GlobeNewswire) -22.24%
Apr-06-22 07:30AM	Context Therapeutics® to Participate in Two April 2022 Investor Conferences (GlobeNewswire)
Mar-30-22 04:33PM	A number of insiders bought Context Therapeutics Inc. (NASDAQ:CNTX) stock last year, which is great news for shareholders (Simply Wall St.)
Mar-23-22 04:01PM	Context Therapeutics® Reports Full Year 2021 Operating and Financial Results (GlobeNewswire)
Mar-08-22 06:12PM	Context Therapeutics® Announces Acceptance of Five Abstracts to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022 (GlobeNewswire) +9.62%
Feb-22-22 07:30AM	Context Therapeutics® to Participate in the Sachs 15th Annual European Life Sciences CEO Forum (GlobeNewswire)
Jan-05-22 04:01PM	Context Therapeutics® Strengthens Research & Development Team (GlobeNewswire) -9.12%
Jan-04-22 07:30AM	Context Therapeutics® to Participate in Two January 2022 Investor Conferences (GlobeNewswire)
Dec-10-21 11:11AM	ORCL Stock: 6 Reasons Why Oracle Investors Are Smiling Today (InvestorPlace) -14.06%
10:11AM	MITC Stock: The Lab-Grown Steak Breakthrough That Has MeaTech3D Looking Tasty Today (InvestorPlace)
09:54AM	CNTX Stock: The Breast Cancer Clinical Trial Data That Has Context Therapeutics Soaring Today (InvestorPlace)
06:45AM	Context Therapeutics Shares Surge On Encouraging Data From Onapristone In Early Breast Cancer (Benzinga)
Dec-09-21 06:00PM	Context Therapeutics® Announces Positive Data from ONA-XR in Early Breast Cancer at 2021 San Antonio Breast Cancer Symposium (GlobeNewswire) +24.21%
Dec-06-21 04:45PM	Context Therapeutics Inc. Announces Closing of $31.25 Million Private Placement (GlobeNewswire)
Dec-02-21 04:01PM	Context Therapeutics® Reports Third Quarter 2021 Operating and Financial Results (GlobeNewswire) -19.97% -7.50%
Dec-01-21 06:30PM	Context Therapeutics Inc. Announces $31.25 Million Private Placement (GlobeNewswire)
Nov-19-21 09:00AM	Context Therapeutics® to Present Clinical Data on ONA-XR in Breast Cancer at 2021 San Antonio Breast Cancer Symposium (GlobeNewswire) +9.89%
Nov-01-21 04:02PM	Context Therapeutics® Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Legal Officer (GlobeNewswire) +6.98%
Oct-27-21 07:30AM	Context Therapeutics® and Wisconsin Oncology Network Announce First Patient Dosed in Phase 2 Trial of ONA-XR in Metastatic Breast Cancer (GlobeNewswire) -7.32%
Oct-22-21 04:05PM	Context Therapeutics® Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters Over-allotment Option (GlobeNewswire) +13.29% +6.58%
Oct-20-21 04:57PM	Bitcoin Miner Stronghold Stock Pops 52% in First Day of Trading (Barrons.com)
Oct-19-21 07:14PM	Context Therapeutics® Announces Pricing of Initial Public Offering (GlobeNewswire)

Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CNTX

Context Therapeutics Inc

Upgrade your FINVIZ experience